Turn Therapeutics Inc. Common Stock (TTRX) - Total Liabilities
Based on the latest financial reports, Turn Therapeutics Inc. Common Stock (TTRX) has total liabilities worth $12.53 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Turn Therapeutics Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Turn Therapeutics Inc. Common Stock - Total Liabilities Trend (2023–2025)
This chart illustrates how Turn Therapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Turn Therapeutics Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Turn Therapeutics Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AGORA INC. SP.ADS/4 CL.A
F:9AG1
|
Germany | €158.25 Million |
|
Bank Ochrony Środowiska SA
WAR:BOS
|
Poland | zł23.28 Billion |
|
Dharma Polimetal Tbk PT
JK:DRMA
|
Indonesia | Rp1.46 Trillion |
|
Hanoi Beer Alcohol and Beverage JSC
VN:BHN
|
Vietnam | ₫1.74 Trillion |
|
Chongqing Wanli New Energy Co Ltd
SHG:600847
|
China | CN¥45.97 Million |
|
RideNow Group, Inc.
NASDAQ:RDNW
|
USA | $686.10 Million |
|
Anhui Fengxing Wear Resistant Materials Co Ltd
SHE:002760
|
China | CN¥406.24 Million |
Liability Composition Analysis (2023–2025)
This chart breaks down Turn Therapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Turn Therapeutics Inc. Common Stock stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Turn Therapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Turn Therapeutics Inc. Common Stock (2023–2025)
The table below shows the annual total liabilities of Turn Therapeutics Inc. Common Stock from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.48 Million | +235.78% |
| 2024-12-31 | $2.23 Million | +15.49% |
| 2023-12-31 | $1.93 Million | -- |
About Turn Therapeutics Inc. Common Stock
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and de… Read more